We are live on ! Find out more
HALO icon

Halozyme

167 hedge funds and large institutions have $1.56B invested in Halozyme in 2017 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 76 increasing their positions, 41 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

710% more call options, than puts

Call options by funds: $34.9M | Put options by funds: $4.3M

85% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 41

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

4% more funds holding

Funds holding: 160167 (+7)

5% more capital invested

Capital invested by funds: $1.49B → $1.56B (+$69.7M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

1.48% less ownership

Funds ownership: 88.71%87.22% (-1.5%)

Holders
167
Holders Change
+7
Holders Change %
+4.38%
% of All Funds
4.16%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
25
Increased
76
Reduced
41
Closed
18
Calls
$34.9M
Puts
$4.3M
Net Calls
+$30.6M
Net Calls Change
+$15.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Fisher Asset Management
26
Fisher Asset Management
Washington
$7.87M -$33.3K -2,490 -0.4%
Millennium Management
27
Millennium Management
New York
$7.57M +$4.68M +350,572 +146%
GIP
28
Granite Investment Partners
California
$7.25M +$7.55M +565,507 New
KCM
29
Kennedy Capital Management
Missouri
$7M -$2.01M -150,245 -22%
Morgan Stanley
30
Morgan Stanley
New York
$6.8M +$256K +19,151 +4%
Charles Schwab
31
Charles Schwab
California
$6.56M +$615K +46,040 +10%
Macquarie Group
32
Macquarie Group
Australia
$6.41M +$534K +40,000 +9%
FLAM
33
First Light Asset Management
Minnesota
$5.34M +$26.3K +1,968 +0.5%
Goldman Sachs
34
Goldman Sachs
New York
$5.23M +$2.64M +197,857 +94%
Two Sigma Investments
35
Two Sigma Investments
New York
$5.02M +$5.23M +391,412 New
Deutsche Bank
36
Deutsche Bank
Germany
$4.84M +$1.73M +129,669 +52%
O
37
OrbiMed
New York
$4.49M +$4.67M +350,000 New
Wells Fargo
38
Wells Fargo
California
$4.45M +$582K +43,542 +14%
SEI Investments
39
SEI Investments
Pennsylvania
$4.29M +$338K +25,300 +8%
FAM
40
Fred Alger Management
New York
$4.25M -$436K -32,620 -9%
Adage Capital Partners
41
Adage Capital Partners
Massachusetts
$4.17M +$3.01M +225,000 +225%
CEP
42
Chicago Equity Partners
Illinois
$4.04M +$1.94M +145,410 +86%
RCMNY
43
Rubric Capital Management (New York)
New York
$3.85M +$4.01M +300,000 New
TCIM
44
TIAA CREF Investment Management
New York
$3.79M -$574 -43 -0%
CS
45
Credit Suisse
Switzerland
$3.16M -$198K -14,861 -6%
CS
46
Candriam SCA
Luxembourg
$3.1M +$334K +25,000 +12%
Citadel Advisors
47
Citadel Advisors
Florida
$3.04M +$2.75M +206,052 +671%
BG
48
Bellevue Group
Switzerland
$2.81M -$681K -51,000 -19%
GC
49
Guggenheim Capital
Illinois
$2.73M +$382K +28,570 +16%
Swiss National Bank
50
Swiss National Bank
Switzerland
$2.65M +$347K +26,000 +14%

HALO Hedge Fund Activity: Q2 2017 in Review

167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q2 2017, worth a combined $1.56B — up 4.7% from $1.49B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new HALO positions and 18 closed out — a net gain of 7 holders — while 76 added to existing stakes and 41 trimmed.

The largest buyer was MSD Partners, adding an estimated $19.8M. The largest seller was VOYA Investment Management, cutting an estimated $20M.

  • 167 institutional investors held Halozyme (HALO) as of Q2 2017, up from 160 in Q1 2017.
  • Funds reported $1.56B of Halozyme stock for Q2 2017, up 4.7% quarter-over-quarter.
  • 25 funds opened new Halozyme positions in Q2 2017 and 18 closed out, a net change of +7 holders.
  • The largest Halozyme buyer in Q2 2017 was MSD Partners, an estimated $19.8M added.
  • The largest Halozyme seller in Q2 2017 was VOYA Investment Management, an estimated $20M sold.

Based on aggregated 13F filings for Q2 2017.